Clinical Trial Update: The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study [NA]

View source ↗

Summary

A pilot study is evaluating the safety of nafamostat mesylate for patients at high risk of bleeding undergoing hemodialysis, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Nafamostat Mesylate (nafamostat)

Snippet

Sponsor: Wonju Severance Christian Hospital | Conditions: Dialysis; Complications, Bleeding | NA | Status: RECRUITING